Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Idarucizumab

  • A Case Example: Reversing Anticoagulant Dabigatran with Idarucizumab

    The Case A 75-year-old man presents to your emergency department via paramedics. His transport time was about...
  • New-Drug Details: Reversing Anticoagulant Dabigatran with Idarucizumab

    Idarucizumab (Praxbind) is the first and only specific reversal agent for a novel oral anticoagulant (NOAC) approved...
  • Pearls from Emergency Medicine Literature on Pulmonary Problems, Bleeding, Evaluating Pediatric Injuries, and More

    Last month, I highlighted some of the most impactful, talked-about, or interesting articles published across the spectrum...

A Case Example: Reversing Anticoagulant Dabigatran with Idarucizumab

February 5, 2019 - W. Richard Bukata, MD - 0 Comment

The Case A 75-year-old man presents to your emergency department via paramedics. His transport time was about…

Read More

New-Drug Details: Reversing Anticoagulant Dabigatran with Idarucizumab

February 5, 2019 - Mary Choy, PharmD, BCGP, FASHP - 1 Comment

Idarucizumab (Praxbind) is the first and only specific reversal agent for a novel oral anticoagulant (NOAC) approved…

Read More

Pearls from Emergency Medicine Literature on Pulmonary Problems, Bleeding, Evaluating Pediatric Injuries, and More

November 12, 2017 - Ryan Patrick Radecki, MD, MS - 1 Comment

Last month, I highlighted some of the most impactful, talked-about, or interesting articles published across the spectrum…

Read More

Results Confirm Idarucizumab’s Ability to Restore Clotting in Dabigatran Recipients

August 1, 2017 - Gene Emery (Reuters Health) - 0 Comment

The blood thinning effects of dabigatran (Pradaxa) can be quickly and reliably reversed by giving idarucizumab (Praxbind)…

Read More
Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603